Back

Systematical analysis reveals the novel function of Cyp2c29 in liver injury

Zhu, Y.; Wang, Q.; Tang, Q.; Zhao, L.; Zhang, Q.; Wu, Y.; Hu, H.; Liu, L.-L.; Liu, X.; Guo, A.-Y.; Yang, X.

2019-09-09 bioinformatics
10.1101/763581 bioRxiv
Show abstract

As a severe lethal cancer, hepatocellular carcinoma (HCC) usually originates from chronic liver injury and inflammation, in which the discovery of key genes is important for HCC prevention. Here, we analyzed the time serial (from 0 week to 30 weeks) transcriptome data of liver injury samples in diethylnitrosamine (DEN)-induced HCC mouse model. Through expression and function analyses, we identified that Cyp2c29 was a key gene continuously downregulated during liver injury. Overexpression of Cyp2c29 suppressed the NF-{kappa}B activation, proinflammatory cytokine production and hepatocyte proliferation by increasing its production 14,15-epoxyeicosatrienoic acid (14,15-EET). Furthermore, in vivo Cyp2c29 protected against liver inflammation in liver injury mice models by reversing the expression on functions of cell proliferation, metabolism and inflammation including suppressing NF-{kappa}B pathway and compensatory proliferation. CYP2C8 and CYP2C9, two human homologs of mouse Cyp2c29, were decreased in human HCC progression and positively correlated with HCC patient survival. Therefore, through systematical analysis and verification, we identified that Cyp2c29 is a novel gene in liver injury and inflammation, which may be a potential biomarker for HCC prevention and prognosis.

Matching journals

The top 16 journals account for 50% of the predicted probability mass.

1
eLife
● 5828 papers in training set
Top 13%
8.1%
Similar papers in this journal
2
Frontiers in Genetics
○ 230 papers in training set
Top 0.3%
6.4%
Similar papers in this journal
3
International Journal of Molecular Sciences
○ 494 papers in training set
Top 2%
5.0%
Similar papers in this journal
4
Toxicological Sciences
◐ 41 papers in training set
Top 0.1%
4.4%
Similar papers in this journal
5
PLOS ONE
● 5266 papers in training set
Top 34%
3.5%
Similar papers in this journal
6
Scientific Reports
○ 3612 papers in training set
Top 30%
3.3%
7
Frontiers in Oncology
○ 103 papers in training set
Top 1%
2.5%
8
The FASEB Journal
○ 194 papers in training set
Top 2%
2.5%
9
iScience
○ 1154 papers in training set
Top 10%
2.5%
10
Antioxidants
○ 25 papers in training set
Top 0.2%
2.5%
11
Genomics, Proteomics & Bioinformatics
188 papers in training set
Top 1%
1.8%
12
PeerJ
◐ 308 papers in training set
Top 5%
1.8%
13
Toxicology and Applied Pharmacology
○ 14 papers in training set
Top 0.1%
1.7%
14
Frontiers in Cell and Developmental Biology
○ 233 papers in training set
Top 3%
1.5%
15
Computational Biology and Chemistry
○ 28 papers in training set
Top 0.4%
1.5%
16
Genes
○ 144 papers in training set
Top 2%
1.5%
50% of probability mass above
17
Gene
○ 46 papers in training set
Top 0.9%
1.4%
18
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
○ 26 papers in training set
Top 0.4%
1.4%
19
BioMed Research International
○ 28 papers in training set
Top 1%
1.2%
20
Biochemical and Biophysical Research Communications
○ 84 papers in training set
Top 1%
1.2%
21
Heliyon
○ 152 papers in training set
Top 5%
1.2%
22
Biomolecules
○ 100 papers in training set
Top 2%
1.2%
23
International Immunopharmacology
○ 15 papers in training set
Top 0.2%
1.2%
24
FASEB BioAdvances
○ 18 papers in training set
Top 0.2%
1.2%
25
Life Sciences
○ 27 papers in training set
Top 0.7%
1.2%
26
Biomedicines
○ 67 papers in training set
Top 2%
1.2%
27
International Journal of Biological Sciences
● 10 papers in training set
Top 0.1%
1.1%
28
British Journal of Pharmacology
○ 40 papers in training set
Top 0.6%
1.1%
29
Virologica Sinica
○ 11 papers in training set
Top 0.1%
1.1%
30
Biology
○ 45 papers in training set
Top 0.6%
0.9%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.